umu.sePublikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
External Validity of the ARISTOTLE Trial in Real-Life Atrial Fibrillation Patients
Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Medicin.
Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Medicin.
Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Medicin.
Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Medicin.
2014 (engelsk)Inngår i: Cardiovascular Therapeutics, ISSN 1755-5914, Vol. 32, nr 5, s. 214-218Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Objective

Our primary objective was to determine the proportion of patients with atrial fibrillation (AF) eligible for enrollment in a randomized controlled trial for a novel oral anticoagulant, the ARISTOTLE trial. A secondary objective was to describe the reasons for trial ineligibility.

Methods

We performed a cross-sectional study of an unselected population including 2274 patients in Skelleftea, Sweden with at least one verified episode of AF on or before December 31, 2010. Patients were classified as suitable or unsuitable for anticoagulant treatment according to current guidelines. The enrollment criteria from the ARISTOTLE trial were extracted from the original publication and applied to the population.

Results

Among all patients with AF, 1579 were classified as suitable for anticoagulant treatment. Of these, only 658 patients (42%) were eligible for participation in the ARISTOTLE trial. Among the 921 patients ineligible for participation, 498 did not meet the ECG criteria, 272 had psychosocial problems, and in addition, 78 patients were excluded due to both of these criteria.

Conclusion

Our study shows that a majority of the patients in an unselected population with AF suitable for anticoagulant treatment were ineligible for participation in the ARISTOTLE trial. The applicability of the ARISTOTLE trial is therefore unknown for a considerable proportion of patients with AF in real life.

sted, utgiver, år, opplag, sider
2014. Vol. 32, nr 5, s. 214-218
Emneord [en]
Apixaban, ARISTOTLE, Arrhythmias, Atrial fibrillation, Coagulation, Thrombosis, External validity
HSV kategori
Identifikatorer
URN: urn:nbn:se:umu:diva-96617DOI: 10.1111/1755-5922.12087ISI: 000342852700005PubMedID: 24975869OAI: oai:DiVA.org:umu-96617DiVA, id: diva2:766680
Tilgjengelig fra: 2014-11-28 Laget: 2014-11-24 Sist oppdatert: 2018-06-07bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstPubMed

Personposter BETA

Jansson, Jan-HåkanJohansson, Lars

Søk i DiVA

Av forfatter/redaktør
Jansson, Jan-HåkanJohansson, Lars
Av organisasjonen
I samme tidsskrift
Cardiovascular Therapeutics

Søk utenfor DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 146 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf